National and Kapodistrian University of Athens
Ανάλυση της έκφρασης και μελέτη των γονιδίων DDC και BCL2L12 σε καρκινικά κύτταρα και ιστούς νεφρού: διερεύνηση της διαφοροδιαγνωστικής και προγνωστικής τους αξίας
Abstract
dc:descriptionΚidney cancer accounts for 2.1% of all malignancies diagnosed worldwide, while renal cell carcinoma (RCC) is its most common type (90%). Recently, several studies emphasize on the need to find novel molecular markers that could contribute in the fields of diagnosis, prognosis and monitoring of therapy in RCC. Toward this direction, we conducted a clinical evaluation of the mRNA levels of the genes L-DOPA decarboxylase (DDC) and BCL2L12 and their corresponding regulatory microRNAs in surgically removed renal tissue specimens and cultured renal cancer cells exposed to anticancer drugs. For that purpose, we firstly collected 58 cancerous and 44 non-cancerous renal tissue samples and furthermore cultured and treated with the antineoplastic agents gemcitabine, sunitinib, and everolimus the established cancer cell line Caki-1. In parallel, by conducting a search in the literature we tried to trace regulatory microRNAs for BCL2L12 and DDC. Regarding the former, we managed to retrieve a study reporting validated interaction between miR-182 and BCL2L12. As for DDC, due to lack of data, a number of microRNA candidates was firstly gathered by using specifically developed bioinformatic tools and those of high probability were then examined for their validity by developing an adequate methodology, which ultimately led us to the identification of miR-145 as a regulatory microRNA for DDC expression. After that, we proceeded with the development of four quantitative real-time PCR protocols in order to assess the transcript levels of BCL2L12, DDC, miR-182 and miR-145 and sequentially our data were subjected to statistical analysis in relation to the clinicopathological features of renal tissue specimens or exposure conditions of tumor cells. According to our results, DDC was downregulated in malignant samples, showing also high diagnostic sensitivity and specificity as per ROC curve analysis (AUC=0.910). In addition, mRNA levels of DDC were correlated with the histological subtype and the degree of malignancy of cancerous samples. Regarding BCL2L12, this likewise demonstrated downregulation in malignant renal tissues, also showing high diagnostic sensitivity and specificity according to ROC curve analysis (AUC=0.725). Instead, though, no statistically significant correlation between the BCL2L12 mRNA levels and the clinicopathological features of the cancerous samples emerged. Moving to the clinical evaluation of miR-145, its levels also demonstrated downregulation in tumor samples together with high diagnostic sensitivity and specificity (AUC = 0.616), while miR-145 expression was significantly correlated with the histologic subtype and the stage of the disease. On the contrary, miR-182 showed no significant correlation with the status of the samples or their clinicopathological parameters. As for our cell culture experiments, significant alterations were detected only in the case of miR-145 and specifically with regard to the cancer cells exposed to sunitinib and everolimus. In conclusion, the completion of the present study revealed that the mRNA levels of DDC and BCL2L12, as well as the RNA levels of miR-145 could be considered as promising molecular markers for kidney cancer. In addition, within the framework of this study we provided evidence that miR-145 has the ability to regulate the gene expression of DDC.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2015
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papadopoulos, Emmanouil
- Παπαδόπουλος, Εμμανουήλ
Subjects
dc:subject × 16Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/43318